Ryde Group Ltd. faces a class action lawsuit alleging violations of securities laws due to false and misleading statements during March to September 2024. The lawsuit claims Ryde used social media misinformation and fake financial experts to inflate its stock price, allowing insiders to sell shares at inflated values. Investors who bought shares during this period and suffered losses are encouraged to join the case before the November 9, 2026 deadline to seek recovery.
Ryde Group Ltd. faces a class action lawsuit alleging securities law violations. For readers following Financials-sector stocks, here is Pluang's market snapshot as of Oct 05, 2026 11:51 WIB: of 85 priced Financials-sector US stocks tradable on Pluang, 47 rose and 36 fell today. Notable prices include GPN at USD 78.46 with a 1-day change of -3.93%, BBVA at USD 26.98 with -3.19%, and MCO at USD 440.01 with -3.13%.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
